{
  "id": 16203072,
  "title": "Multiple Sclerosis Anti-CD20 Drug Linked to Bowel Disease Risk",
  "url": "https://urgent.news/2026/10/23/multiple-sclerosis-anti-cd20-drug-linked-to-bowel-disease-risk",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-23T14:56:12.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/meetingcoverage/ectrims/123547"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- The anti-CD20 agent rituximab was associated with a higher risk of inflammatory bowel disease (IBD) in people with relapsing-remitting multiple sclerosis (MS) compared with other disease-modifying treatments (DMTs), a population...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}